Physician profile
Caleb Christopher Jones
NPI 1447830161
$2,318.36
in general payments reported to CMS, 2019-2025
22 companies · $1,636 in 2025
The $1,636 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $112 · 2024: $570 · 2025: $1,636.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,318.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,318.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $362.25 | 2024-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $297.29 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Abbvie INC. | $260.66 | 2024-2025 | |
| Glaxosmithkline, LLC. | $258.64 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Vertex Pharmaceuticals Incorporated | $245.47 | 2025 | |
| Pfizer INC. | $159.84 | 2025 | |
| Phathom Pharmaceuticals, INC. | $124.97 | 2024 | Voquezna |
| Novo Nordisk INC | $99.60 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Exact Sciences Corporation | $97.35 | 2024-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $83.10 | 2024 | Dexcom G7 Gss (161) |
| Insulet Corporation | $59.28 | 2025 | Omnipod |
| Bayer Healthcare Pharmaceuticals INC. | $50.06 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $37.93 | 2025 | Gemtesa |
| Corium, LLC | $33.84 | 2024 | Azstarys |
| Astellas Pharma US INC | $26.74 | 2025 | Veozah |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $20.67 | 2025 | Heplisav-B |
| Gilead Sciences, INC. | $19.79 | 2024 | Epclusa |
| Chiesi USA, INC. | $17.35 | 2024 | Mycapssa |
| Seqirus USA INC | $17.19 | 2025 | Flucelvax, Fluad |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.47 | 2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $15.70 | 2025 | Rexulti |
| Amgen INC. | $14.17 | 2025 | Repatha, Otezla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caleb Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.